Insider Selling: Atreca, Inc. (NASDAQ:BCEL) Insider Sells 10,000 Shares of Stock
Atreca, Inc. (NASDAQ:BCEL) insider Tito Serafini sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $15.02, for a total value of $150,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Tito Serafini also recently made the following trade(s):
- On Friday, December 11th, Tito Serafini sold 10,000 shares of Atreca stock. The stock was sold at an average price of $15.87, for a total value of $158,700.00.
- On Monday, November 16th, Tito Serafini sold 8,847 shares of Atreca stock. The stock was sold at an average price of $15.12, for a total value of $133,766.64.
BCEL stock opened at $14.77 on Thursday. The stock has a market capitalization of $542.16 million, a PE ratio of -5.24 and a beta of 0.08. Atreca, Inc. has a 12-month low of $10.88 and a 12-month high of $29.35. The stock’s 50 day simple moving average is $15.71 and its 200 day simple moving average is $15.11.
BCEL has been the topic of a number of analyst reports. Zacks Investment Research cut Atreca from a “buy” rating to a “hold” rating in a research report on Friday, October 9th. BidaskClub cut Atreca from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 30th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. Atreca presently has an average rating of “Buy” and an average target price of $26.40.
A number of hedge funds have recently added to or reduced their stakes in BCEL. Bank of Montreal Can bought a new position in Atreca in the 2nd quarter valued at approximately $34,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Atreca during the 3rd quarter valued at $40,000. Great West Life Assurance Co. Can bought a new position in shares of Atreca during the 2nd quarter valued at $41,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Atreca by 723.4% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 6,966 shares of the company’s stock valued at $97,000 after buying an additional 6,120 shares during the period. Finally, Exane Derivatives lifted its holdings in shares of Atreca by 88.9% during the 3rd quarter. Exane Derivatives now owns 8,068 shares of the company’s stock valued at $113,000 after buying an additional 3,798 shares during the period. 69.64% of the stock is currently owned by institutional investors and hedge funds.
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Featured Story: How do investors use RSI to grade stocks?
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.